首页> 美国卫生研究院文献>Drug Design Development and Therapy >Development and validation of an oxygen dissociation assay a screening platform for discovering and characterizing hemoglobin–oxygen affinity modifiers
【2h】

Development and validation of an oxygen dissociation assay a screening platform for discovering and characterizing hemoglobin–oxygen affinity modifiers

机译:氧离解测定法的开发和验证一种用于发现和表征血红蛋白-氧亲和性修饰剂的筛选平台

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionHemoglobin (Hb) is a critical molecule necessary for all vertebrates to maintain aerobic metabolism. Hb–oxygen (O2) affinity modifiers have been studied to address various diseases including sickle cell disease, hypoxemia, tumor hypoxia, and wound healing. However, drug development of exogenous Hb modifiers has been hindered by the lack of a technique to rapidly screen compounds for their ability to alter Hb–O2 affinity. We have developed a novel screening assay based upon the spectral changes observed during Hb deoxygenation and termed it the oxygen dissociation assay (ODA).
机译:简介血红蛋白(Hb)是所有脊椎动物维持有氧代谢所必需的关键分子。已经对Hb-氧(O2)亲和性修饰剂进行了研究,以解决各种疾病,包括镰状细胞病,低氧血症,肿瘤缺氧和伤口愈合。但是,由于缺乏快速筛选化合物改变Hb-O2亲和力的技术,阻碍了外源性Hb修饰剂的药物开发。我们已经基于在Hb脱氧过程中观察到的光谱变化开发了一种新颖的筛选测定法,并将其称为氧离解测定法(ODA)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号